6986 Stock Overview
Engages in the research and development of stem cell and treatments in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
HeXun Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$70.40 |
| 52 Week High | NT$85.30 |
| 52 Week Low | NT$40.00 |
| Beta | 0 |
| 11 Month Change | -9.28% |
| 3 Month Change | 4.92% |
| 1 Year Change | 3.38% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6986 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | 0.6% | -3.0% | -3.4% |
| 1Y | 3.4% | -14.4% | 30.2% |
Return vs Industry: 6986 exceeded the TW Life Sciences industry which returned -14.4% over the past year.
Return vs Market: 6986 underperformed the TW Market which returned 30.2% over the past year.
Price Volatility
| 6986 volatility | |
|---|---|
| 6986 Average Weekly Movement | 4.1% |
| Life Sciences Industry Average Movement | 4.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6986 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6986's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 35 | n/a | www.hexunbio.com |
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell and treatments in Taiwan. It provides outsourced production services; commissioned development and manufacturing services for various cells and cell derivatives; commissioned inspection; advisory; laboratory information management system; and sterile filling services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
HeXun Biosciences Co., Ltd. Fundamentals Summary
| 6986 fundamental statistics | |
|---|---|
| Market cap | NT$3.24b |
| Earnings (TTM) | NT$124.21m |
| Revenue (TTM) | NT$236.41m |
26.1x
P/E Ratio13.7x
P/S RatioIs 6986 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6986 income statement (TTM) | |
|---|---|
| Revenue | NT$236.41m |
| Cost of Revenue | NT$19.70m |
| Gross Profit | NT$216.71m |
| Other Expenses | NT$92.50m |
| Earnings | NT$124.21m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.70 |
| Gross Margin | 91.67% |
| Net Profit Margin | 52.54% |
| Debt/Equity Ratio | 0% |
How did 6986 perform over the long term?
See historical performance and comparison